Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rezolute, Inc.

NASDAQ: RZLT · Life Sciences · 7 alerts · CIK 1509261

Rezolute, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.58Close, Nov 16
Market cap
$346M
Shares outstanding
96.72MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rezolute, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Capital Raise

Rezolute Capital Raise of $100M

Rezolute, Inc. entered into an underwriting agreement for a public offering of 22,040,976 shares of common stock and 3,800,000 pre-funded warrants, expected to raise gross proceeds of approximately $100 million. The financing was led by Frazier Life Sciences and is intended to fund commercialization preparation for ersodetug and general corporate purposes.

Value
$100M
Counterparty
Frazier Life Sciences
6:27 AM ET 8-K
Clinical Trial Data

Rezolute Clinical Trial Data

Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism. The study met its primary efficacy endpoint with 13 of 16 participants achieving at least a 50% reduction in glucose infusion rate, including 12 who completely discontinued IV glucose. The company expects to report full topline results in mid-December 2026 and engage with the FDA in Q1 2027.

Term
8 weeks
4:18 PM ET 8-K
Financial Results

Rezolute Financial Results

Rezolute, Inc. reported financial results for its first fiscal quarter ended September 30, 2026, ending the period with $90.0 million in cash and investments. The company provided clinical updates on its ersodetug program, noting that enrollment is complete for the Phase 3 upLIFT study in tumor HI with topline results expected in December 2026, and plans to submit a BLA for one or both HI indications in 2027.

Term
Q1 2027
4:15 PM ET 8-K
Investor Presentation

Rezolute Investor Presentation

Rezolute, Inc. released an updated corporate investor presentation on October 29, 2026, highlighting its late-stage clinical programs for ersodetug in treating refractory hypoglycemia. The company reported a cash position of $108 million, providing a projected operational runway through the first quarter of 2028.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.